ActualEyes

ActualEyes is a clinical-stage biotechnology company headquartered in Japan, dedicated to researching and developing cell therapies and drug therapies for corneal endothelial dysfunctions such as Fuchs' Endothelial Corneal Dystrophy (FECD) and bullous keratopathy. The company was founded based on the related research achievements of Professor Noriko Koizumi and Professor Naoki Okumura from Doshisha University in Kyoto, Japan. Our commitment is to provide this new drug therapy and cell therapy to patients and society with a positive and swift attitude.